Biomarin

Why BioMarin's Shares Tumbled 11% in June
Motley Fool
Sun, 07/10/16 - 12:09 pm
Biomarin
M&A
Duchenne Muscular Dystrophy
Sanofi
drisapersen
Kyndrisa
BioMarin Pharmaceutical shares rise after possible takeover from Roche
CNBC
Thu, 07/7/16 - 04:02 pm
Biomarin
M&A
Roche
3 Plausible Buyout Scenarios Within Biotech
Seeking Alpha
Tue, 07/5/16 - 10:20 am
biotech
Acadia
AstraZeneca
Allergan
Biogen
Teva Pharmaceutical
Biomarin
Incyte
Ironwood
Medivation
Pfizer
Relypsa
Synergy Pharmaceuticals
M&A
These 15 Biotech Companies Could Be Takeover Targets
Barron's
Wed, 06/29/16 - 12:56 pm
biotech
M&A
Alder Biopharmaceuticals
Biomarin
Coherus Biosciences
Intercept Pharma
Ultragenyx
Seattle Genetics
Adamas Pharmaceuticals
Alexion
Clovis Oncology
Corbus Pharmaceuticals
Incyte
Prothena
Puma Biotechnology
Tesaro
Versartis
BioMarin climbs on rumors it may be Sanofi's Medivation backup
Fierce Pharma
Fri, 06/17/16 - 09:38 pm
Biomarin
Sanofi
Medivation
M&A
Biotech: Is the Rally Real?
Barron's
Thu, 06/2/16 - 04:01 pm
biotech
Prothena
Biomarin
Vertex Pharmaceuticals
Incyte
Celgene
Why BioMarin’s Bad News is Great for Sarepta
Barron's
Wed, 06/1/16 - 09:43 pm
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
BioMarin to Stop Developing its Duchenne Muscle Disease Drug
Bloomberg
Tue, 05/31/16 - 09:56 pm
Biomarin
Duchenne Muscular Dystrophy
Kyndrisa
3 Biotech Stocks Buoyed By Potential Blockbuster Drugs
Investors.com
Sat, 05/7/16 - 01:13 pm
JCAR015
Juno Therapeutics
Kyndrisa
Biomarin
Intercept Pharma
Ocaliva
BioMarin announces 'encouraging' early-stage hemophilia therapy data
Marketwatch
Wed, 04/20/16 - 09:37 am
Biomarin
hemophilia
BMN 270
BioMarin drug for genetic disorder succeeds in late-stage study
Yahoo/Reuters
Mon, 03/21/16 - 09:01 am
Biomarin
clinical trials
pegvaliase
5 Key FDA Decisions Expected in March
24/7 Wall St
Mon, 03/14/16 - 10:02 am
FDA
Rayaldee
OPKO Health
Nuplazid
Acadia
abaloparatide
Radius Health
pegvaliase
Biomarin
ALD403
Alder Biopharmaceuticals
Sanofi scouts for rare disease buyouts as Shire bears down on the field
Fierce Biotech
Tue, 03/1/16 - 09:37 am
Sanofi
Shire
M&A
R&D
Biomarin
Ionis Pharmaceuticals
Ultragenyx
Why the FDA shouldn’t bow to parental pressure over Duchenne drug
Stat
Tue, 01/26/16 - 09:17 pm
FDA
Duchenne Muscular Dystrophy
drug approvals
Biomarin
Sarepta Therapeutics
BioMarin Fails to Win Approval for Drug to Treat Deadly Duchenne
Bloomberg
Thu, 01/14/16 - 10:07 am
Biomarin
FDA
Duchenne Muscular Dystrophy
Kyndrisa
drisapersen
4 Top FDA Decisions Expected in Q1
24/7 Wall St
Mon, 01/4/16 - 10:05 am
FDA
Zafgen
beloranib
Biomarin
Peg-Pal
PB272
Puma Biotechnology
Aquinox
AQX-1125
What Does 2016 Hold for Biotech Stocks?
Motley Fool
Sun, 01/3/16 - 10:27 pm
biotech
Gilead Sciences
Celgene
Amgen
Regeneron
Sanofi
Biomarin
Sarepta Th
How Gilead Sciences M&A Can Pan Out Next Year
Bidness, ETC
Tue, 12/29/15 - 09:36 am
Gilead Sciences
M&A
Vertex Pharmaceuticals
Incyte
Biomarin
Regeneron
BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date
Yahoo
Fri, 12/18/15 - 09:07 am
Biomarin
FDA
drisapersen
Kyndrisa
Duchenne Muscular Dystrophy
FDA Committee Raises Concerns about Kyndrisa’s Efficacy, Safety
Yahoo/Market Realist
Fri, 12/11/15 - 10:27 pm
FDA
Kyndrisa
Duchenne Muscular Dystrophy
Biomarin
drisapersen

Pages